These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 23979759

  • 21. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.
    Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF.
    J Antimicrob Chemother; 2016 Jan; 71(1):162-9. PubMed ID: 26503667
    [Abstract] [Full Text] [Related]

  • 23. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T, Otsuki M, Hatano K, Nishihara Y.
    Chemotherapy; 1994 Jan; 40(3):167-82. PubMed ID: 8205935
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
    Flamm RK, Farrell DJ, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):449-56. PubMed ID: 24529941
    [Abstract] [Full Text] [Related]

  • 25. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA, Flamm RK, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

  • 28. In vitro activity of ceftaroline against bacterial isolates causing skin and soft tissue and respiratory tract infections collected in Latin American countries, ATLAS program 2016-2020.
    Mohamed N, Valdez RR, Fandiño C, Baudrit M, Falci DR, Murillo JDC.
    J Glob Antimicrob Resist; 2024 Mar; 36():4-12. PubMed ID: 38016592
    [Abstract] [Full Text] [Related]

  • 29. In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018.
    Jean SS, Lee WS, Ko WC, Hsueh PR.
    J Microbiol Immunol Infect; 2021 Aug; 54(4):627-631. PubMed ID: 32451293
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Nov; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 34. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
    Jones RN, Farrell DJ, Mendes RE, Sader HS.
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii69-80. PubMed ID: 21482572
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.